Nicotinic cholinergic antagonists: A novel approach for the treatment of autism

Medical Hypotheses

Volumn 66, Issue 5, 2006, Pages 985-990

  Lippiello, P M ^a  

^a TARGACEPT INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; GALANTAMINE; HALOPERIDOL; IVERSINE; MECAMYLAMINE; METHYLPHENIDATE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; RIVASTIGMINE;

ARTICLE; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; AUTISM; CHOLINERGIC ACTIVITY; CHOLINERGIC RECEPTOR BLOCKING; CHOLINERGIC SYSTEM; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE ASSOCIATION; DOPAMINE RELEASE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; HUMAN; INFANTILE AUTISM; LOW DRUG DOSE; MAJOR DEPRESSION; NEUROANATOMY; PAIN; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SMOKING; SMOKING CESSATION;

AUTISTIC DISORDER; CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; HUMANS; MENTAL DISORDERS; NEURODEGENERATIVE DISEASES; NICOTINIC ANTAGONISTS;

EID: 32144460018     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2005.11.015     Document Type: Article

References (35)

1. R.T. Schultz Developmental deficits in social perception in autism: the role of the amygdale and fusiform face area Int J Dev Neurosci 23 2005 125 141
2. L.Y. Tsai Psychopharmacology in autism Psychosom Med 61 1999 651 665
3. M.L. Bauman, and T.L. Kemper Neuroanatomic observations of the brain in autism: a review and future directions Int J Dev Neurosci 23 2005 183 187
4. Lam KSL, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil 2005 [in press].
5. A.A. Jensen, B. Frolund, T. Liljefors, and P. Krogsgaard-Larsen Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations J Med Chem 48 2005 4704 4745
6. S. Wonnacott Presynaptic nicotinic ACh receptors Trends Neurosci 20 1997 92 98
7. M.K. Belmonte, E.H. Cook Jr., and G.M. Anderson Autism as a disorder of neural information processing: directions for research and targets for therapy Mol Psychiatry 9 2004 646 663
8. D. Murray, M. Lesser, and W. Lawson Attention, monotropism and the diagnostic criteria for autism Autism 9 2005 139 156
9. Smith J, Diller H. Attention deficit hyperactivity disorder (ADHD), 〈 www.learning-apodixis.com/attention-deficit-disorder-adhd.asp〉 > 2005 [accessed 14.09.05].
10. C. Gotti, and F. Clementine Neuronal nicotinic receptors: from structure to pathology Prog Neurobiol 74 2004 363 396
11. R.C. Hogg, and D. Bertrand Nicotinic acetylcholine receptors as drug targets Curr Drug Targets CNS Neurol Disord 3 2004 2004 123 130
12. E.D. Levin, and A.H. Rezvani Nicotinic treatment for cognitive dysfunction Curr Drug Targets CNS Neurol Disord 1 2002 423 431
13. E.D. Levin, C.K. Conners, D. Silva, W. Canu, and J. March Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder Exp Clin Psychopharmacol 9 2001 83 90
14. R.D. Shytle, A.A. Silver, R.J. Lukas, M.B. Newman, D.V. Sheehan, and P.R. Sanberg Nicotinic acetylcholine receptors as targets for antidepressants Mol Psychiatry 7 2002 525 535
15. K.P. Tercyak, C. Lerman, and J. Audrain Association of attention deficit/hyperactivity disorder with levels of cigarette smoking in a community sample of adolescents J Am Acad Child Adolesc Psychiatry 41 2002 799 805
16. M.F. Poirier, O. Canceil, F. Bayle, B. Millet, M.C. Bourdel, and C. Moatti Prevalence of smoking in psychiatric patients Prog Neuropsychopharmacol Biol Psychiatry 26 2002 529 537
17. S. Bejerot, and L. Nylander Low prevalence of smoking in patients with autism spectrum disorders Psychiatry Res 119 2003 177 182
18. E.K. Perry, M.L.W. Lee, and C.M. Martin-Ruiz Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain Am J Psychiatry 158 2001 2001 1058 1066
19. C.M. Martin-Ruiz, M. Lee, R.H. Perry, J.A. Baumann, J.A. Court, and E.K. Perry Molecular analysis of nicotinic receptor expression in autism Mol Brain Res 123 2004 81 90
20. M.A. Ray, A.J. Graham, M. Lee, R.H. Perry, J.A. Court, and E.K. Perry Neuronal nicotinic acetylcholine receptor subunits in autism: an immunohistochemical investigation in the thalamus Neurobiol Dis 19 2005 366 377
21. A.Y. Hardan, and B.L. Handen A retrospective open trial of adjunctive Donepezil in children and adolescents with autistic disorder J Child Adolesc Psychopharmacol 12 2002 237 241
22. M. Hertzman Galantamine in the treatment of adult autism: a report of three clinical cases Int J Psychiatry Med 33 2003 395 398
23. M.G. Chez, M. Aimonovitch, T. Buchana, S. Mrazek, and R.J. Tremb Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate J Child Neurol 19 2004 165 169
24. M.L. Baumann, and T.L. Kemper Neuroanatomic observations of the brain in autism M.L. Baumann T.L. Kemper The neurobiology of autism 1994 Johns Hopkins University Press Baltimore 119 145
25. M. Cordero-Erausquin, S. Pons, P. Faure, and J.P. Changeux Nicotine differentially activates inhibitory and excitatory neurons in the dorsal spinal cord Pain 109 2004 308 318
26. L.E. Rueter, M.D. Meyer, and M.W. Decker Spinal mechanisms underlying A-85380-induced effects on acute thermal pain Brain Res 872 2000 93 101
27. J. Kerbeshian, L. Burd, and K. Avery Pharmacotherapy of autism: a review and clinical approach J Dev Phys Disabil 13 2001 199 228
28. K.A. Sacco, J.C. Vessicchio, and T.P. George Nicotinic antagonist augmentation of SSRI antidepressants: preliminary results Biol Psychiatry 55 2004 Abstract 235S
29. Autism Research Institute Report. Parent ratings of behavioral effects of biomedical interventions. ARI Publ. 34, 〈 www.autismwebsite.com/ari/ treatment/form34q.htm 〉 2005 [accessed 16.9.05].
30. D.J. Cohen, B.K. Caparulo, B.A. Shaywitz, and M.B. Bowers Jr. Dopamine and serotonin metabolism in neuropsychiatrically disturbed children. CSF homovanillic acid and 5-hydroxyindoleacetic acid Arch Gen Psychiatry 34 1977 545 550
31. S. Wonnacott, N. Sidhpura, and D.J. Balfour Nicotine: from molecular mechanisms to behaviour Curr Opin Pharmacol 5 2005 53 59
32. A.A. Silver, R.D. Shytle, K.H. Sheehan, D.V. Sheehan, A. Ramos, and P.R. Sanberg Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder J Am Acad Child Adolesc Psychiatry 40 2001 1103 1110
33. R.D. Shytle, A.A. Silver, and P.R. Sanberg Comorbid bipolar disorder in Tourette's syndrome responds to the nicotinic receptor antagonist mecamylamine (Inversine) Biol Psychiatry 48 2000 1028 1031
34. A.V. Terry Jr., J.J. Buccafusco, and M.A. Prendergast Dose-specific improvements in memory-related task performance by rats and aged monkeys administered the nicotinic-cholinergic antagonist mecamylamine Drug Dev Res 47 1999 127 136
35. Ankenman R. Personal communication; 2005.